Relapsed Refractory Large B-Cell Lymphoma Treatment Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is relapsed refractory large B-cell lymphoma treatment market size?

USD 1,053.6 million in 2026 and USD 2,471.5 million by 2036 at an 8.9% CAGR.

Sales of relapsed refractory large B-cell lymphoma treatment market are estimated to rise at 8.9% CAGR through 2036, increasing valuation from USD 1,053.6 million in 2026 to USD 2,471.5 million by 2036. Oncology teams now choose cellular and antibody options much earlier in the treatment cycle. Strong survival data directly drives this shifting clinical approach. In February 2025, a USA Food and Drug Administration publication highlighted this progress with the report analyzing an ECHELON-3 study population of 230 patients. This crucial trial supported brentuximab vedotin with lenalidomide and rituximab. Such a combination targets relapsed or refractory large B-cell lymphoma and the randomized evidence offers new options for patients who cannot undergo stem-cell transplantation. It also provides a viable path forward for individuals ineligible for CAR-T therapy. Resulting with such clinical insights helping hospitals selecting effective protocols for vulnerable individuals.

Diverse regulatory frameworks influence doctors adopting new lymphoma treatments globally. United States and Germany treatment centers favor earlier-line evidence due to established cell-therapy services. Networks in South Korea and the UK promote treatments compatible with national reimbursement. New clinical updates provide essential data to guide these regional decisions. Genmab reported an EPCORE DLBCL-1 progression-free survival hazard ratio of 0.74 in January 2026. This metric evaluated epcoritamab and lenalidomide against a combination of rituximab along with gemcitabine and oxaliplatin. Comparative trial results are likely to directly influence upcoming formulary reviews. Such reviews specifically involve patients unsuitable for intensive salvage therapy. Resulting with regional adaptations ensuring oncology teams to deliver practical care based on local guidelines.

Summary of Relapsed Refractory Large B-Cell Lymphoma Treatment Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Clinical demand expands as oncologists seek treatments producing durable responses among patients experiencing relapse or resistance. Earlier-line evidence and reduced referral delays support broader treatment access across hematology programs. Hematology teams assess therapies capable of improving disease control following frontline treatment failure. Specialist referral networks influence timely movement from confirmed relapse into advanced treatment pathways. Hospital committees value comparative survival evidence and adverse-event management protocols during formulary review. Outpatient administration is anticipated to reduce bed pressure for selected antibody and cellular-therapy regimens. Treatment-center education access is projected to influence adoption across regional oncology services.
Product and Segment View	Second-Line leads line-of-therapy demand, followed by hospitals and CAR-T cell therapy across established hematology programs. Treatment selection is expected to center on response durability and practical delivery requirements across eligible patient groups. Second-line is predicted to garner 40.4% share in 2026, led by earlier intervention following frontline treatment failure. Hospitals are anticipated to represent 33.7% share in 2026, helped by infusion capacity and adverse-event monitoring. CAR-T cell therapy is likely to secure 33.4% share in 2026, guided by durable remission evidence among eligible patients.
Geography and Growth Outlook	Country movement differs according to treatment-center capacity and reimbursement timing. Referral speed and specialist access influence the pace of adoption. Commercial progress reflects national payer support for advanced lymphoma regimens. USA is forecast to expand at 10.1% CAGR by 2036, aided by extensive treatment-center capacity and rapid regimen adoption. Germany is projected to rise at 9.4% CAGR during the forecast period, driven by university hospitals and structured reimbursement. South Korea is estimated to record 8.9% CAGR from 2026 to 2036, backed by concentrated tertiary-care infrastructure.
Competitive View	Competition involves cellular therapy and CD20xCD3 bispecific antibodies. Antibody-drug conjugates and targeted combinations provide additional treatment choices. Roche and Genentech are expected to compete based on Polivy and Lunsumio across antibody-based treatment pathways. Gilead Sciences and Kite are projected to retain a prominent cellular-therapy position depending on Yescarta. AbbVie and Genmab are anticipated to strengthen Epkinly review due to subcutaneous administration and continuing combination trials.
Analyst Perspective	Commercial progress is expected to favor therapies supported by comparative trials and practical treatment-center protocols. Companies providing referral support and treatment education may secure sustained clinical review. Manufacturing reliability and continuing patient assistance strengthen hospital confidence. Treatment programs assess remission durability beside manufacturing time and hospitalization requirements. Payer acceptance improves when clinical evidence clarifies patient eligibility and treatment sequencing. Regional education access supports safe expansion across newly participating hematology centers. - Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights

Source: Future Market Insights analysis, 2026.

How is relapsed refractory large B-cell lymphoma treatment market segmented?

The relapsed refractory large B-cell lymphoma treatment market is segmented by therapy type, drug, line of therapy, end user, and region.

The relapsed refractory large B-cell lymphoma treatment market is segmented by therapy type, drug, line of therapy, end user, and region. Therapy type coverage begins with CAR-T cell therapy and bispecific antibodies. Antibody-drug conjugates and monoclonal antibodies extend treatment assessment. Chemotherapy combinations complete therapy type coverage. Drug analysis reviews Polivy, Lunsumio, and Columvi across antibody-based regimens. Yescarta, Breyanzi, and Kymriah cover cellular treatment. Epkinly completes drug assessment. Line-of-therapy analysis separates second-line care from third-line and later treatment. End-user coverage distinguishes hospitals from cancer centers. Specialty oncology clinics and academic institutes complete end-user assessment. Regional analysis follows the geographic structure listed in the report scope.

Why does CAR-T Cell Therapy shape therapy type selection?

Gilead Sciences reported in December 2025 stating a pooled two-year overall survival rate of 64.9% for Yescarta across comparative second-line analyses. Durable survival evidence strengthens clinical consideration of engineered cell therapy among eligible patients experiencing early relapse following initial chemoimmunotherapy. Treatment-center certification and manufacturing coordination remain central to successful delivery.

• CAR-T cell therapy is estimated to garner 33.4% share of therapy type in 2026, driven by durable remission outcomes among eligible patients with refractory disease or early relapse. Certified centers manage cell collection and manufacturing; clinical teams then supervise infusion and recovery.
• Bispecific antibodies provide ready-to-administer treatment for patients lacking access or eligibility for cellular therapy. Antibody-based alternatives remain useful in later lines as clinicians adapt treatment to prior exposure and current disease behavior.

Why does Polivy shape drug selection?

Combination evidence positions Polivy for review within targeted oncology biologics strategies intended to extend remission without cellular manufacturing. Roche reported in June 2025 a median progression-free survival period of 11.5 months for Lunsumio combined with Polivy among patients with relapsed or refractory large B-cell lymphoma.

• By drug, polivy is anticipated to command 27.6% share in 2026 owing to established combination use among transplant-ineligible and heavily treated patients. Hospital teams review previous therapy and marrow reserve, examining infection risk and treatment-related neuropathy during regimen selection.
• Lunsumio and Columvi provide CD20xCD3 treatment under separate dosing schedules with Epkinly adding a subcutaneous option with its own monitoring plan. Yescarta and Breyanzi require patient-specific manufacturing with Kymriah following the same treatment-center pathway.

Why does Second-Line lead line-of-therapy demand?

Genmab announced in June 2025 an overall response rate of 87% for investigational epcoritamab plus R-ICE among transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma. High response activity encourages earlier assessment of next-generation immunotherapies among patients requiring rapid disease control following frontline failure.

• Second-line is projected to represent 40.4% share in 2026, driven by earlier CAR-T use and developing bispecific combinations following frontline failure. Clinical teams compare relapse timing with transplant eligibility, confirming access to specialist treatment centers.
• Third-line care uses advanced therapies selected according to previous exposure and remaining treatment options. Fourth-line and later care requires careful sequencing to limit repeated toxicity, and address resistant disease.

Why do hospitals lead end-user demand?

Hospital hematology programs are likely to gain operational flexibility as cellular-therapy experience expands. A USA Food and Drug Administration action issued in June 2025 removed Risk Evaluation and Mitigation Strategy requirements for 6 approved autologous CAR-T cell immunotherapies. Revised requirements reduce administrative demands for certified dispensing and retain boxed warnings with post-treatment safety monitoring.

• Based on end-user, hospitals are forecast to secure 33.7% share in 2026 owing to infusion infrastructure and immediate specialist access. Clinical teams monitor cellular and bispecific therapies closely, enabling early identification of immune-related complications.
• Cancer centers and specialty oncology clinics extend treatment access through referral relationships with cellular-therapy institutions. Academic institutes contribute research capacity for biomarker studies and clinical evaluation of new antibody therapy.

What are drivers, restraints, and opportunities in relapsed refractory large B-cell lymphoma treatment market?

Clinical demand reflects treatment failure following frontline chemoimmunotherapy and limited remission durability across heavily treated populations. Adoption may slow as referral complexity and manufacturing delays interrupt timely treatment.

• Driver: Earlier-line evidence encourages treatment teams to assess bispecific antibodies and antibody-drug conjugates sooner following documented relapse.
• Restraint: Complex toxicity monitoring and specialist requirements limit routine administration among facilities lacking experienced hematology teams or emergency support.
• Opportunity: Outpatient regimens and fixed-duration combinations may extend advanced treatment access beyond major academic centers through structured referral and monitoring arrangements.

Roche reported in May 2025 a 40% overall-survival improvement for Columvi combined with gemcitabine and oxaliplatin compared to rituximab and oxaliplatin. Such improvement favors earlier bispecific-antibody adoption among transplant-ineligible patients requiring a readily available treatment. Comparative evidence may strengthen payer and clinical-guideline evaluation across later-line blood cancer treatment pathways.

Adverse-event management remains a limiting condition for advanced treatment expansion. Gilead Sciences reported in June 2025 grade-three-or-higher cytokine release syndrome among 9% of large B-cell lymphoma patients represented in Yescarta safety information. Treatment centers require trained staff and rapid escalation protocols. Continuing follow-up supports safe management of immune-mediated events.

Genmab reported in September 2025 first-full-dose outpatient administration for 92% of patients during EPCORE NHL-6 evaluation. Outpatient delivery could reduce bed pressure across centers prepared for structured observation. Treatment expansion remains dependent upon patient selection and clear transfer arrangements.

How are country CAGRs aligned in relapsed refractory large B-cell lymphoma treatment market?

Country or Market	CAGR
USA	10.1%
Germany	9.4%
South Korea	8.9%
UK	7.3%
Japan	7.0%

Source: Future Market Insights analysis, 2026.

How do country-level CAGRs compare in relapsed refractory large B-cell lymphoma treatment market?

Country forecasts show a gradual decline from USA to Japan across the profiled comparison. Germany and South Korea occupy the next positions through specialist capacity and organized treatment access. UK and Japan progress at a measured pace under public reimbursement structures. Trial availability and coverage timing create separate adoption conditions across national treatment systems.

• USA records the leading profiled rate, aided by extensive certified treatment centers and earlier access to newly approved therapies.
• Germany ranks second as university hospitals and regulated care pathways encourage advanced lymphoma treatment adoption.
• South Korea follows through concentrated tertiary-care infrastructure and coordinated national coverage decisions.
• UK posts measured expansion as national assessment processes and specialist referral channels govern treatment access.
• Japan closes the comparison through centralized clinical expertise and structured post-treatment monitoring practices.

Comparable CAGRs do not produce identical access conditions across profiled countries. North America and Latin America begin the geographic assessment. Western Europe and Eastern Europe receive separate regional evaluations. East Asia, South Asia and Pacific, and Middle East and Africa complete report coverage.

Country-wise Analysis

• Relapsed refractory large B-cell lymphoma treatment market in the United States is estimated to grow at 10.1% CAGR during the forecast period, driven by extensive cellular-therapy capacity and rapid uptake of newly approved regimens. Major oncology networks coordinate specialist referrals and clinical-trial access. Experienced teams also manage adverse events across cellular and antibody-based treatment programs. USA Census Bureau data released in June 2025 recorded 61.2 million residents aged 65 years or older during 2024, expanding the population requiring hematologic cancer assessment and age-adapted treatment pathways.
• German Federal Statistical Office data published in June 2025 showed residents aged 65 years or older represented 23.2% of Germany’s population during 2024. An older demographic increases clinical need for transplant-ineligible regimens and outpatient antibody treatment delivered through university hospitals. Sector in Germany is predicted to record 9.4% CAGR between 2026 and 2036 as structured reimbursement enables hematology centers to participate in multicenter European trials.
• Concentrated tertiary hospitals enable advanced diagnosis and cellular-therapy delivery within metropolitan treatment networks. Industry in South Korea is projected to scale at 8.9% CAGR during the study period, backed by specialist capacity and coordinated national coverage decisions accelerate treatment access. Bank of Korea analysis issued in June 2025 reported people aged 65 years or older represented 20% of the national population at year-end 2024, strengthening demand for treatment pathways suitable for older lymphoma patients.
• Office for National Statistics estimates published in September 2025 placed the UK population at 69.3 million during mid-2024, indicating a sizeable national pool requiring hematology and oncology services. Sales in the United Kingdom are set to rise at 7.3% CAGR from 2026 to 2036, guided by specialized treatment centers and national technology assessment. Referral timing may influence access to CAR-T treatment outside major teaching hospitals. Regional infusion capacity also affects bispecific therapy availability.
• Centralized cancer hospitals and disciplined post-treatment monitoring enable measured use of cellular therapies and bispecific antibodies. Statistics Bureau of Japan reported in April 2025 a population of 36.243 million residents aged 65 years or older during 2024, reinforcing clinical demand for regimens suitable for older and transplant-ineligible patients. Demand in Japan is forecast to expand at 7.0% CAGR over 2026 to 2036, reflecting specialist review and gradual reimbursement expansion.

Who are notable companies in relapsed refractory large B-cell lymphoma treatment market?

F. Hoffmann-La Roche Ltd. and Genentech maintain participation led by Polivy along with Columvi, and Lunsumio. Gilead Sciences and Kite address cellular treatment driven by Yescarta. Bristol Myers Squibb supplies Breyanzi. Novartis supports Kymriah, and AbbVie works with Genmab on Epkinly combination studies.

Regeneron Pharmaceuticals supports later-line diffuse large B-cell lymphoma treatment in Europe due to Ordspono. Pfizer and Takeda participate based on Adcetris development and commercialization arrangements. Incyte supports tafasitamab-based treatment through Monjuvi or Minjuvi in approved territories. Competition is projected to center on remission durability and treatment duration. Safety management and patient eligibility influence the administration setting. Cellular-therapy suppliers are expected to compete driven by manufacturing reliability and certified-center support. Bispecific-antibody companies may emphasize ready availability and outpatient administration. Antibody-drug conjugate suppliers are likely to seek combination roles among patients unsuitable for intensive cellular treatment.

• F. Hoffmann-La Roche Ltd. and Genentech are expected to maintain a diversified lymphoma portfolio spanning antibody-drug conjugates and CD20xCD3 bispecific antibodies. Clinical review is likely to focus on sequencing Polivy and Lunsumio across treatment lines.
• Gilead Sciences and Kite are anticipated to retain a prominent cellular-therapy position depending on Yescarta. Treatment-center support and manufacturing reliability are expected to guide continuing adoption across eligible second-line patients.
• Bristol Myers Squibb is projected to compete through Breyanzi and its differentiated cellular-therapy evidence base. Clinical teams may examine outpatient administration and earlier-line use during product comparison. Safety management remains part of the final review.
• AbbVie and Genmab are estimated to strengthen review of Epkinly through subcutaneous administration and continuing combination trials. Outpatient transition protocols could influence use across hospital and regional cancer programs.
• Regeneron and Incyte are likely to compete due to targeted antibody portfolios addressing later-line treatment needs. Pfizer and Takeda add antibody-drug conjugate participation. Commercial progress is expected to reflect approved indications and geographic reimbursement.

Competitive Benchmarking: Relapsed Refractory Large B-Cell Lymphoma Treatment Market

Company	Portfolio Depth	Clinical Match	Service Support	Service Reach
F. Hoffmann-La Roche Ltd./Genentech, Inc.	High	High	High	Global oncology presence
Gilead Sciences, Inc./Kite, a Gilead Company	High	High	High	International cellular-therapy network
Bristol Myers Squibb	High	High	High	Multi-country certified treatment centers
Novartis AG	High	High	High	International treatment-center coverage
AbbVie Inc.	High	High	High	Hospital and outpatient programs
Genmab A/S	High	High	Medium	North America, Europe, and selected Asian markets
Regeneron Pharmaceuticals, Inc.	Medium	High	Medium	European commercial access
Pfizer Inc.	High	Medium	High	Global oncology channels
Incyte Corporation	Medium	Medium	Medium	North America, Europe, and Japan
Takeda Pharmaceutical Company Limited	High	Medium	High	International markets outside selected Pfizer territories

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Relapsed Refractory Large B-Cell Lymphoma Treatment Market

• In January 2025, Bristol Myers Squibb announced Health Canada approval of Breyanzi for second-line treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. Approval expanded access to CAR-T therapy among patients experiencing early relapse or resistance following frontline treatment.
• In April 2025, Roche announced European Commission approval of Columvi combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma following initial therapy. Company findings reported a 41% reduction in the risk of death, supporting fixed-duration bispecific treatment review for transplant-ineligible patients.
• In June 2026, Genmab announced positive Phase III EPCORE DLBCL-4 results for epcoritamab plus lenalidomide among patients with relapsed or refractory diffuse large B-cell lymphoma. Company information reported a statistically significant progression-free survival improvement, supporting further review of a chemotherapy-free combination.

Key Players in Relapsed Refractory Large B-Cell Lymphoma Treatment Market

Cellular-therapy companies

• Gilead Sciences, Inc./Kite, a Gilead Company
• Bristol Myers Squibb
• Novartis AG

Bispecific-antibody and antibody-drug conjugate companies

• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• AbbVie Inc.
• Genmab A/S
• Regeneron Pharmaceuticals, Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited

Targeted antibody participant

• Incyte Corporation

Relapsed Refractory Large B-Cell Lymphoma Treatment Market Report Scope

Coverage field	Report scope
Market breakdown	Relapsed refractory large B-cell lymphoma treatment market breakdown by therapy type, drug, line of therapy, end user, and region.
Quantitative Units	USD million in 2026 to USD million by 2036 at CAGR
Market Definition	Treatments used for large B-cell lymphoma returning following prior therapy or failing to produce adequate disease control.
Regions Covered	Coverage includes North America and Latin America. Western Europe and Eastern Europe form separate assessments. East Asia, South Asia and Pacific, and Middle East and Africa complete the regional scope.
Countries Covered	North America includes USA and Canada. Latin America covers Brazil and Mexico. Europe includes Germany, France, UK, Italy, and Spain. Asian coverage includes China, Japan, South Korea, India, and Australia. GCC countries and other national markets complete the scope.
Key Companies Profiled	Cellular-therapy profiles include Gilead Sciences, Kite, Bristol Myers Squibb, and Novartis. Antibody-focused profiles include Roche, Genentech, AbbVie, Genmab, Regeneron, Pfizer, Incyte, and Takeda.
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down analysis uses therapy adoption and patient eligibility. Treatment sequencing, regulatory activity, trial evidence, and country access conditions inform the forecast.

Source: Future Market Insights analysis, 2026.

Relapsed Refractory Large B-Cell Lymphoma Treatment Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Source: Future Market Insights analysis, 2026.

Relapsed Refractory Large B-Cell Lymphoma Treatment Market by Segments

Relapsed Refractory Large B-Cell Lymphoma Treatment Market segmented by Therapy Type:

• CAR-T Cell Therapy
• Bispecific Antibodies
• Antibody-Drug Conjugates
• Monoclonal Antibodies
• Chemotherapy and Combination Therapy

Relapsed Refractory Large B-Cell Lymphoma Treatment Market segmented by Drug:

• Polivy (Polatuzumab Vedotin)
• Lunsumio (Mosunetuzumab)
• Columvi (Glofitamab)
• Yescarta
• Breyanzi
• Kymriah
• Epkinly

Relapsed Refractory Large B-Cell Lymphoma Treatment Market segmented by Line of Therapy:

• Second-Line
• Third-Line
• Fourth-Line and Later

Relapsed Refractory Large B-Cell Lymphoma Treatment Market segmented by End User:

• Hospitals
• Cancer Centers
• Specialty Oncology Clinics
• Academic and Research Institutes

Relapsed Refractory Large B-Cell Lymphoma Treatment Market segmented by Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• East Asia
• South Asia and Pacific
• Middle East and Africa

Research Sources and Bibliography

• Bristol Myers Squibb. (2025, January 13). CAR T-cell therapy Breyanzi approved for second-line relapsed or refractory diffuse large B-cell lymphoma.
• Bank of Korea. (2025, June 23). Toward sustainable employment for older workers in aging Korea [BOK Issue Note 2025-08].
• Genmab A/S. (2025, June 15). Genmab announces epcoritamab investigational combination therapy demonstrates high response rates in relapsed or refractory diffuse large B-cell lymphoma.
• Genmab A/S. (2025, September 3). Genmab announces updated results from the Phase II EPCORE NHL-6 trial.
• Genmab A/S. (2026, January 16). Genmab announces topline results for epcoritamab from the Phase III EPCORE DLBCL-1 trial.
• Genmab A/S. (2026, June 29). Genmab announces positive Phase III results for epcoritamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
• German Federal Statistical Office. (2025, June 20). Population by age groups (from 2011).
• Gilead Sciences, Inc. (2025, June 1). Kite presents new real-world data supporting use of potentially curative Yescarta in outpatient care for patients with relapsed or refractory large B-cell lymphoma at ASCO 2025.
• Gilead Sciences, Inc. (2025, December 7). Yescarta delivers consistent safety, efficacy, and quality-of-life benefits across relapsed or refractory large B-cell lymphoma analyses at ASH 2025.
• Office for National Statistics. (2025, September 26). Population estimates for the UK, England, Wales, Scotland and Northern Ireland: Mid-2024.
• Roche. (2025, April 14). European Commission approves Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy.
• Roche. (2025, May 23). New two-year follow-up of Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients.
• Roche. (2025, June 20). Roche’s Lunsumio and Polivy combination significantly prolongs remission in relapsed or refractory large B-cell lymphoma.
• Statistics Bureau of Japan. (2025, April 14). Current population estimates as of October 1, 2024.
• USA Census Bureau. (2025, June 26). Older adults outnumber children in 11 states and nearly half of USA counties.
• USA Food and Drug Administration. (2025, February 11). FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma.
• USA Food and Drug Administration. (2025, June 27). FDA eliminates Risk Evaluation and Mitigation Strategies for autologous chimeric antigen receptor CAR T-cell immunotherapies.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• What segments influence demand across therapy type, drug, line of therapy, end user, and region?
• How do hematology teams evaluate advanced lymphoma treatments prior to routine clinical use?
• How do country CAGRs differ across profiled markets with distinct treatment-center capacity and reimbursement access?
• What companies compete through cellular therapy, bispecific antibodies, antibody-drug conjugates, and targeted antibody combinations?
• How are forecasts validated through hybrid bottom-up and top-down analysis using independent clinical and commercial indicators?
• What evidence do hospital committees examine prior to adding advanced lymphoma regimens?
• How do response durability and adverse-event management influence treatment selection?
• What limits return on investment for hospitals adding complex cellular-therapy services?
• How do education records and specialist guidance influence hospital approval across hematology teams?
• What company capabilities improve long-term clinical confidence and continuing therapy utilization?